Advanced manufacturing for biodegradable microfluidic diagnostic devices

可生物降解微流体诊断设备的先进制造

• 批准号: 10045280
• 金额: $ 6.37万
• 依托单位: DEVICE SCOPE LTD
• 依托单位国家: 英国
• 项目类别: Grant for R&D
• 财政年份: 2022
• 资助国家: 英国
• 起止时间: 2022 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=10045280
• 关键词: Advanced; manufacturing; biodegradable; microfluidic; diagnostic

This project aims to enable the successful commercialisation of more lab-quality tests at the Point-of-Care whilst minimising the environmental impact of their disposable components.Microfluidic technology enables the transfer of high-quality lab assays into Point-of-Care testing devices. These tests enable infectious disease detection (e.g. Covid-19) or chronic disease monitoring (e.g. diabetes, chronic heart disease, etc) with high quality molecular, immunoassay and clinical chemistry assays to be completed by anyone in the home, work or health care worker setting. Fast uptake of this microfluidic technology has been hindered by the significant investments and time to market required for the product development and establishment of high-volume manufacturing lines.Device Scope aims to dramatically improve the commercialisation of microfluidic diagnostic products whilst minimising the impact of these disposable tests on the environment by developing a new manufacturing system for microfluidic devices that utilises biodegradable materials. This project will assess the biodegradable material using our unique manufacturing techniques and subsequently build prototype microfluidic devices for assessment.

该项目旨在使更多的实验室质量检测在床旁检测成功商业化，同时最大限度地减少其一次性组件对环境的影响。微流体技术使高质量的实验室检测转移到床旁检测设备中。这些测试使传染病检测（例如Covid-19）或慢性疾病监测（例如糖尿病，慢性心脏病等）能够通过高质量的分子，免疫测定和临床化学分析由任何人在家庭，工作或卫生保健工作者环境中完成。由于产品开发和大批量生产线的建立所需的大量投资和上市时间，阻碍了这种微流控技术的快速发展。Device Scope旨在通过开发一种新的微流控设备制造系统，利用可生物降解材料，极大地提高微流控诊断产品的商业化，同时最大限度地减少这些一次性测试对环境的影响。该项目将使用我们独特的制造技术评估可生物降解材料，并随后构建原型微流体设备进行评估。